Article
11 Apr 2023
Celltrion Announces Phase III Results For Aflibercept Biosimilar
AUTHORS CONTENT
Article
02 Feb 2023
FDA Commissioner Delivers Remarks At FDA-U.S. Patent And Trademark Office Public Workshop
Article
31 Jan 2023
An Interview With Rachel Goode, Ph.D, About Biological Patent Thickets
Article
17 Oct 2022
Amgen Releases 2022 Biosimilar Trends Report
Article
13 Oct 2022
Recent And Proposed Legislation Affecting Biosimilars
Article
09 Sep 2022
Biocon And Alvotech Release Statements On FDA Inspections
Article
03 Aug 2022
FDA Accepts For Review Fresenius Kabi's BLA For Tocilizumab Biosimilar
Article
29 Jun 2022
Formycon Q1 2022 Financial Results And Announcement Of Two New Biosimilar Products
Article
25 May 2022
EMA Recommends Denying Marketing Authorization For Prestige BioPharma's TUZNUE And HERVELOUS (trastuzumab)
Article
22 Apr 2022
FDA Approves Amneal's ALYMSYS (bevacizumab-maly)
Article
23 Mar 2022
JAMA Oncology Publishes Results Of Phase III Study For Prestige BioPharma's HERCEPTIN Biosimilar, HD201
Article
11 Feb 2022
FDA Approves Genentech's VABYSMO For Wet AMD And Diabetic Macular Edema